DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $2,322 | +13.2% | 100 | 0.0% | 0.00% | 0.0% |
| Q1 2024 | $2,052 | -4.4% | 100 | 0.0% | 0.00% | 0.0% |
| Q4 2023 | $2,146 | +4.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q3 2023 | $2,063 | -30.1% | 100 | 0.0% | 0.00% | -50.0% |
| Q2 2023 | $2,951 | +28.1% | 100 | 0.0% | 0.00% | +100.0% |
| Q1 2023 | $2,304 | -17.2% | 100 | 0.0% | 0.00% | -50.0% |
| Q4 2022 | $2,781 | -7.3% | 100 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $3,000 | 0.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $3,000 | 0.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $3,000 | -25.0% | 100 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $4,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $404,042,000 | 54.41% |
| Bratton Capital Management, L.P. | 953,035 | $19,785,000 | 29.05% |
| Flagship Pioneering Inc. | 8,005,747 | $166,199,000 | 7.19% |
| Casdin Capital, LLC | 400,000 | $8,304,000,000 | 0.78% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $91,561,000 | 0.65% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 22,595 | $469,000 | 0.37% |
| MARK ASSET MANAGEMENT LP | 70,532 | $1,464,000 | 0.34% |
| Artal Group S.A. | 400,000 | $8,304,000 | 0.34% |
| PIER 88 INVESTMENT PARTNERS LLC | 27,650 | $574,000 | 0.24% |
| WASATCH ADVISORS LP | 996,147 | $20,680,000 | 0.20% |